Validated HPLC–PDA methodology utilized for simultaneous determination of Etoricoxib and Paracetamol in the presence of Paracetamol toxic impurities
Open Access
- 2 December 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Chemistry
- Vol. 16 (1), 1-11
- https://doi.org/10.1186/s13065-022-00904-z
Abstract
Etoricoxib (ETO), Paracetamol (PCM), and two toxic impurities for Paracetamol impurity K (4-aminophenol (PAP)) and impurity E (para-hydroxy acetophenone (PHA)) were separated using a simple and selective HPLC method that was tested for the first time. PCM is a commonly used analgesic and antipyretic medication that has recently been incorporated into COVID-19 supportive treatment. Pharmaceuticals containing PCM in combination with other analgesic-antipyretic drugs like ETO help to improve patient compliance. The studied drugs and impurities were separated on a GL Sciences Inertsil ODS-3 (250 × 4.6) mm, 5.0 µm column, and linear gradient elution was performed using 50 mM potassium dihydrogen phosphate adjusted to pH 4.0 with ortho-phosphoric acid and acetonitrile as mobile phase at 2.0 mL/min flow rate at 25 °C and UV detection at 220 nm. The linearity range was 1.5–30.0 µg/mL for ETO and PCM while 0.5–10.0 µg/mL for PAP and PHA, with correlation coefficients (r) for ETO, PCM, PAP, and PHA of 0.9999, 0.9993, 0.9996, and 0.9998, respectively. The proposed method could be used well for routine analysis in quality control laboratory.Keywords
Funding Information
- Cairo University
This publication has 42 references indexed in Scilit:
- Validated RP-HPLC Method for the Assay of Etoricoxib (A Non-Steroidal Anti-Inflammatory Drug) in Pharmaceutical Dosage FormsE-Journal of Chemistry, 2012
- HPLC Separation of Acetaminophen and its Impurities Using A Mixed-mode Reversed-Phase/Cation Exchange Stationary PhaseJournal of Chromatographic Science, 2012
- Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain managementPublished by BMJ ,2011
- Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography–inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2009
- Validation of a fluorimetric assay for 4-aminophenol in paracetamol formulationsTalanta, 2008
- Determination of etoricoxib in pharmaceutical formulations by HPLC methodIndian Journal of Pharmaceutical Sciences, 2007
- Carcinogenicity categorization of chemicals—new aspects to be considered in a European perspectiveToxicology Letters, 2004
- Clinical pharmacology of etoricoxib: a novel selectiveCOX2 inhibitorExpert Opinion on Pharmacotherapy, 2003
- EtoricoxibDrugs, 2002
- The Role of Amino-Reactive Impurities in Acetylsalicylic Acid AllergyInternational Archives of Allergy and Immunology, 1975